Periodontal Ehlers-Danlos Syndrome · pEDS

Description

Periodontal Ehlers-Danlos syndrome, pEDS, is a rare connective tissue disorder caused by heterozygous pathogenic variants in C1R or C1S, the genes that encode the C1r and C1s subcomponents of the C1 complex of complement. It is the only EDS subtype with a complement-pathway molecular cause, and the only one in which severe early-onset periodontal disease is part of the diagnostic core.

The 2017 international classification (Malfait et al., American Journal of Medical Genetics Part C, 2017) defines pEDS by major criteria that include severe and intractable early-onset periodontitis, lack of attached gingiva, pretibial plaques, and a family history consistent with autosomal dominant inheritance. Minor criteria include easy bruising, joint hypermobility usually limited to distal joints, soft skin, recurrent infections, hernias, and marfanoid facial features. Molecular confirmation requires a heterozygous pathogenic variant in C1R or C1S, identified by Kapferer-Seebacher et al. (American Journal of Human Genetics, 2016) as the genetic basis of the syndrome that had been described clinically since the 1970s.

Periodontitis in pEDS begins in childhood or adolescence, progresses despite standard periodontal care, and leads to loss of permanent teeth in early adulthood without aggressive intervention. The mechanism by which complement-pathway variants drive periodontal connective tissue destruction is not fully resolved. Current models, summarized by Kapferer-Seebacher and colleagues, point to dysregulated complement signaling at the periodontal interface and altered handling of oral microbial communities, rather than a primary defect in collagen synthesis.

Approximately 100 affected individuals have been reported worldwide across the original kindreds and subsequent series. Prevalence is not established.

Treatments to date

No drug therapy targets the underlying complement defect in pEDS. Care centers on aggressive periodontal management delivered by a periodontist familiar with the diagnosis, ideally from the first eruption of permanent teeth.

Standard of care includes intensive plaque control, frequent scaling and root planing, and adjunctive antimicrobial therapy. The periodontal response in pEDS is poorer than in idiopathic aggressive periodontitis at matched disease severity, and the literature documents continued attachment loss despite excellent compliance. Tooth loss in early adulthood is common, and prosthodontic planning starts early. Dental implants, fixed bridges, and removable prostheses are used to restore function. Implant outcomes in pEDS are described in case series rather than controlled studies, and clinicians weigh implant placement against the same connective tissue fragility that drove the original disease.

Pretibial plaques and skin findings are managed conservatively. The systemic EDS features, including joint hypermobility, easy bruising, and hernias, follow the broader EDS playbook of activity modification, wound protection, and surgical caution. Recurrent infections in some affected individuals prompt immunology consultation, and some adults are followed for autoimmune findings reported in pEDS cohorts.

Cardiovascular surveillance is not standard in pEDS in the way it is in vascular EDS, although aortic root dilation has been reported in a minority of cases and warrants baseline echocardiography. Genetic counseling addresses the autosomal dominant inheritance pattern, with a 50 percent recurrence risk for offspring of an affected parent.

No disease-specific drug or registered clinical trial in pEDS exists. Research directions named by recent reviews include the role of C1r and C1s in periodontal connective tissue homeostasis, the contribution of the oral microbiome to disease progression, and whether complement-targeting biologics developed for other indications could be repurposed.